Ehave Inc Stock Price, News & Analysis

Ehave, Inc. (EHVVF) announced a partnership with Health Wizz and BurstIQ to enhance data integrity and patient privacy. This collaboration aims to allow patients to securely share medical data with providers and researchers, crucial for understanding treatments for mental health and substance use disorders. The Ehave Dashboard, developed with a major children's hospital in Canada, will utilize AI and blockchain technology to streamline health processes, enabling better patient outcomes. CEO Ben Kaplan emphasized the importance of data integrity in improving mental health care.

Ehave, Inc. (EHVVF) announced the hiring of an Institutional Review Board (IRB) to oversee its upcoming ketamine clinical trials in Miami with Tristar Wellness. This crucial step ensures the safety of participants and compliance with research protocols. The company plans to launch its KetaDASH platform for at-home ketamine therapy, aiming to enhance patient access and clinic revenues. Ehave is negotiating to franchise the KetaDASH platform across the U.S., and management highlights the potential to expand ketamine therapy research beyond mental health.

Ehave, Inc. (OTC Pink: EHVVF) announced that Dr. Bankole A. Johnson has joined its Medical Advisory Board. Dr. Johnson, a renowned psychiatrist known for his research in psychopharmacology and addiction, will advise on human trials related to cognitive and psychedelic therapies and mental health platforms. His previous roles include chairman at the University of Virginia’s Psychiatry Department and founder of Adial Pharmaceuticals. Dr. Johnson aims to integrate biological mechanisms of addiction with psychedelic medicine to improve patient care.

Ehave, a provider of digital therapeutics for mental health, announced its sponsorship of the upcoming PsyTech Summit, taking place virtually on July 19-20, 2021. The company aims to promote its KetaDASH platform, a HIPAA-compliant cloud solution for at-home ketamine infusion therapy. The summit will explore critical psychedelic topics featuring notable industry speakers. Ehave emphasizes the significance of this event for enhancing visibility and engagement in the psychedelic sector, particularly as it rolls out innovative therapeutic solutions.

Ehave, Inc. announces the addition of Dr. Muneer A. Ali to its Medical Advisory Board, effective July 1, 2021. Dr. Ali, a board-certified clinical psychiatrist and Associate Medical Director at Amen Clinics, will provide guidance on human trials for cognitive and psychedelic therapies. His expertise includes ADHD, anxiety disorders, and substance use disorders. Ehave's Chief Medical Officer highlighted Dr. Ali's invaluable insights as the company progresses in human trials. Ehave focuses on digital therapeutics to improve mental health care, leveraging blockchain technology through its flagship product, the Ehave Dashboard.

Ehave, Inc. (OTC Pink: EHVVF) has appointed Dr. Jeffrey D. Kamlet as its new Chief Medical Officer, bringing over 30 years of experience in internal medicine and addiction. This strategic hire aims to deepen clinical expertise and advance clinical studies on I.V. Ketamine treatments targeting anxiety, depression, and PTSD. Dr. Kamlet, recognized for his work in ibogaine treatment and cardiac safety, expressed enthusiasm for joining Ehave's mission to enhance mental health treatment options. Ehave continues to focus on innovative therapeutics in the mental health sector.

Ehave, Inc. (EHVVF) introduces its Medical and Vaccine Passport aimed at streamlining Covid-19 vaccination verification for small businesses. This tool enables individuals to securely manage health records and vaccination status, providing convenience as mask mandates relax. With over 150 million potential users, the upcoming Ehave Mobile App will facilitate access to electronic health records (EHRs) and billing data. The app aims to empower users to combine their health data from various sources, supporting patient-generated data to enhance healthcare engagement.

Ehave, Inc. (EHVVF) announces a licensing agreement with Health Wizz to enhance its digital health dashboard by integrating medical records management capabilities. This partnership will enable users to securely share their personal health data while ensuring HIPAA compliance. The Health Wizz mobile app, coupled with blockchain technology, aims to empower individuals to manage their health data efficiently. The global market for Electronic Health Records (EHR) is projected to reach $33.41 billion by 2025, highlighting the significance of this advancement in patient care.

Ehave, Inc. (EHVVF) has launched its KetaDASH subsidiary, introducing a HIPAA-compliant platform for at-home ketamine treatments for anxiety, depression, and PTSD.

The service aims to facilitate access to IV ketamine therapy through partnerships with clinics and healthcare providers. With studies showing that up to 85% of ketamine users experience mental health improvements, this initiative addresses the growing demand for alternative mental health solutions.

CEO Ben Kaplan emphasized the importance of providing compassionate care in a home setting.